Skip to main content
    • Aa
    • Aa

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics

  • John S. Albin (a1) and Reuben S. Harris (a1)

Restriction factors are natural cellular proteins that defend individual cells from viral infection. These factors include the APOBEC3 family of DNA cytidine deaminases, which restrict the infectivity of HIV-1 by hypermutating viral cDNA and inhibiting reverse transcription and integration. HIV-1 thwarts this restriction activity through its accessory protein virion infectivity factor (Vif), which uses multiple mechanisms to prevent APOBEC3 proteins such as APOBEC3G and APOBEC3F from entering viral particles. Here, we review the basic biology of the interactions between human APOBEC3 proteins and HIV-1 Vif. We also summarise, for the first time, current clinical data on the in vivo effects of APOBEC3 proteins, and survey strategies and progress towards developing therapeutics aimed at the APOBEC3–Vif axis.

Corresponding author
*Corresponding author: Reuben Harris, Department of Biochemistry, Molecular Biology & Biophysics, Institute for Molecular Virology, Center for Genome Engineering, University of Minnesota, 6-155 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2 R.S. Harris and M.T. Liddament (2004) Retroviral restriction by APOBEC proteins. Nature Reviews Immunology 4, 868-877

3 M.H. Malim and M. Emerman (2008) HIV-1 accessory proteins–ensuring viral survival in a hostile environment. Cell Host and Microbe 3, 388-398

4 T. Gramberg , N. Sunseri and N.R. Landau (2009) Accessories to the crime: recent advances in HIV accessory protein biology. Current HIV/AIDS Reports 6, 36-42

6 S. Schwartz , B.K. Felber and G.N. Pavlakis (1991) Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 183, 677-686

7 N.C. Kan (1986) Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science 231, 1553-1555

8 T.H. Lee (1986) A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 231, 1546-1549

9 J. Sodroski (1986) Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231, 1549-1553

11 K. Strebel (1987) The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328, 728-730

14 A.G. Fisher (1987) The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893

20 J.H. Simon (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Medicine 4, 1397-1400

21 A.M. Sheehy (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650

22 G. Haché (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Current Biology 18, 819-824

23 A. Jarmuz (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296

24 S.K. Petersen-Mahrt , R.S. Harris and M.S. Neuberger (2002) AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418, 99-103

25 R.S. Harris , S.K. Petersen-Mahrt and M.S. Neuberger (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular Cell 10, 1247-1253

26 R.S. Harris (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809

27 B. Mangeat (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103

28 H. Zhang (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98

29 D. Lecossier (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112

30 E.P. Browne , C. Allers and N.R. Landau (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387, 313-321

31 R.K. Holmes (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. Journal of Biological Chemistry 282, 2587-2595

32 E. Miyagi (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. Journal of Virology 81, 13346-13353

33 A.J. Schumacher (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. Journal of Virology 82, 2652-2660

34 K. Shindo (2003) The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Journal of Biological Chemistry 278, 44412-44416

35 E.N. Newman (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology 15, 166-170

36 K.N. Bishop , R.K. Holmes and M.H. Malim (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of Virology 80, 8450-8458

37 K.N. Bishop (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathogens 4, e1000231

38 Y. Iwatani (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Research 35, 7096-7108

39 F. Guo (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. Journal of Virology 80, 11710-11722

40 Y. Yang (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365, 92-100

41 X.Y. Li (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. Journal of Biological Chemistry 282, 32065-32074

42 K. Luo (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Journal of Virology 81, 7238-7248

43 J.L. Mbisa (2007) HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of Virology 81, 7099-7110

44 A.J. Schumacher , D.V. Nissley and R.S. Harris (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proceedings of the National Academy of Sciences of the United States of America 102, 9854-9859

45 P. Turelli (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829

46 H.P. Bogerd (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proceedings of the National Academy of Sciences of the United States of America 103, 8780-8785

47 H. Muckenfuss (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. Journal of Biological Chemistry 281, 22161-22172

48 M.D. Stenglein and R.S. Harris (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. Journal of Biological Chemistry 281, 16837-16841

49 R.K. Holmes , M.H. Malim and K.N. Bishop (2007) APOBEC-mediated viral restriction: not simply editing? Trends in Biochemical Sciences 32, 118-128

50 M. Bonvin and J. Greeve (2008) Hepatitis B: modern concepts in pathogenesis–APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Current Opinion in Infectious Diseases 21, 298-303

51 R.S. Harris (2003) DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nature Immunology 4, 641-643

52 B. Yang (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. Journal of Biological Chemistry 282, 11667-11675

53 R. Chen (2004) Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. Journal of Biological Chemistry 279, 28419-28425

54 L.M. Mansky (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. Journal of Virology 74, 7039-7047

55 S. Priet (2005) HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Molecular Cell 17, 479-490

56 B. Schröfelbauer (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. Journal of Virology 79, 10978-10987

57 S.M. Kaiser and M. Emerman (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase APOBEC3G. Journal of Virology 80, 875-882

58 S.G. Conticello , R.S. Harris and M.S. Neuberger (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology 13, 2009-2013

59 M. Marin (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine 9, 1398-1403

60 A.M. Sheehy , N.C. Gaddis and M.H. Malim (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine 9, 1404-1407

61 K. Stopak (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell 12, 591-601

62 X. Yu (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060

63 A. Mehle (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry 279, 7792-7798

64 A. Mehle (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes and Development 18, 2861-2866

65 Y. Yu (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes and Development 18, 2867-2872

66 S. Kao (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology 77, 11398-11407

67 R. Mariani (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31

68 M. Santa-Marta (2005) HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. Journal of Biological Chemistry 280, 8765-8775

69 S.G. Conticello (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Molecular Biology and Evolution 22, 367-377

70 J.E. Wedekind (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends in Genetics 19, 207-216

72 Q. Li (2009) Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. Journal of Immunology 183, 1975-1982

73 M. OhAinle (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host and Microbe 4, 249-259

74 A. Harari (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. Journal of Virology 83, 295-303

75 L. Tan (2009) Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB Journal 23, 279-287

76 Q. Yu (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. Journal of Biological Chemistry 279, 53379-53386

77 Q. Yu (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Structural and Molecular Biology 11, 435-442

78 K.N. Bishop (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology 14, 1392-1396

79 M.T. Liddament (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current Biology 14, 1385-1391

80 H.L. Wiegand (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Journal 23, 2451-2458

81 Y.H. Zheng (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology 78, 6073-6076

82 J.M. Watts (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460, 711-716

83 M. Janini (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. Journal of Virology 75, 7973-7986

85 J.P. Vartanian (1994) G--> A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proceedings of the National Academy of Sciences of the United States of America 91, 3092-3096

86 V.K. Pathak and H.M. Temin (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proceedings of the National Academy of Sciences of the United States of America 87, 6019-6023

87 T.L. Kieffer (2005) G--> A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. Journal of Virology 79, 1975-1980

88 C. Pace (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Journal of Virology 80, 9259-9269

89 A. Piantadosi (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. Journal of Virology 83, 7805-7814

90 A.M. Land (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. Journal of Virology 82, 8172-8182

91 S.K. Gandhi (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. Journal of Virology 82, 3125-3130

92 N.K. Ulenga (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Research and Human Retroviruses 24, 1285-1290

93 J.M. Kidd (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genetics 3, e63

94 L.C. Mulder , A. Harari and V. Simon (2008) Cytidine deamination induced HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America 105, 5501-5506

95 B. Berkhout and A. de Ronde (2004) APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18, 1861-1863

97 S.K. Pillai , J.K. Wong and J.D. Barbour (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5, 26

98 P. Jern (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathogens 5, e1000367

99 N. Wood (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathogens 5, e1000414

100 J.A. Vázquez-Pérez (2009) APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6, 23

101 X. Jin (2005) APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. Journal of Virology 79, 11513-11516

102 S.J. Cho (2006) APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. Journal of Virology 80, 2069-2072

103 N.K. Ulenga (2008) Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. Journal of Infectious Diseases 198, 486-492

104 M. Biasin (2007) Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. Journal of Infectious Diseases 195, 960-964

105 H. Do (2005) Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. Journal of Infectious Diseases 191, 159-163

106 P. An (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of Virology 78, 11070-11076

107 H.S. Valcke (2006) APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 20, 1984-1986

108 P. An (2009) APOBEC3B deletion and risk of HIV-1 acquisition. Journal of Infectious Diseases 200, 1054-1058

109 M. OhAinle (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. Journal of Virology 80, 3853-3862

110 S.L. Sawyer , M. Emerman and H.S. Malik (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biology 2, E275

111 Y.L. Chiu (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435, 108-114

112 K. Chen (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. Journal of Virology 80, 7645-7657

113 F.R. Santoni de Sio and D. Trono (2009) APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One 4, e6571

114 M. Kamata , Y. Nagaoka and I.S. Chen (2009) Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathogens 5, e1000342

115 M.L. Vetter (2009) Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathogens 5, e1000292

116 F.A. Koning (2009) Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets. Journal of Virology 83, 9474-9485

117 G. Peng (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393-400

118 M. Pion (2006) APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. Journal of Experimental Medicine 203, 2887-2893

119 G. Peng (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. Journal of Experimental Medicine 203, 41-46

120 R.A. Russell and V.K. Pathak (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. Journal of Virology 81, 8201-8210

121 V. Simon (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathogens 1, e6

122 W. Zhang (2008) Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 3, e3963

123 Z. He (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. Journal of Molecular Biology 381, 1000-1011

124 C. Tian (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. Journal of Virology 80, 3112-3115

125 T. Yamashita (2008) Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes and Infection 10, 1142-1149

126 H. Huthoff (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathogens 5, e1000330

127 H. Huthoff and M.H. Malim (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. Journal of Virology 81, 3807-3815

128 R.A. Russell (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. Journal of Virology 83, 1992-2003

129 L. Zhang (2008) Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370, 113-121

130 E. Pery (2009) Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. Journal of Virology 83, 2374-2381

131 G. Chen (2009) A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. Journal of Virology 83, 8674-8682

132 Y. Dang (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. Journal of Virology 83, 8544-8552

133 E. Harjes (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. Journal of Molecular Biology 389, 819-832

134 R. Nathans (2008) Small-molecule inhibition of HIV-1 Vif. Nature Biotechnology 26, 1187-1192

135 K.M. Chen (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119

136 L.G. Holden (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124

137 A. Furukawa (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO Journal 28, 440-451

138 C. Prochnow (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445, 447-451

139 R. Bransteitter , C. Prochnow and X.S. Chen (2009) The current structural and functional understanding of APOBEC deaminases. Cellular and Molecular Life Sciences 66, 3137-3147

140 R.T. Mitsuyasu (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine 15, 285-292

141 G. Hutter (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New England Journal of Medicine 360, 692-698

142 J.J. Rossi , C.H. June and D.B. Kohn (2007) Genetic therapies against HIV. Nature Biotechnology 25, 1444-1454

143 H.P. Bogerd (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the United States of America 101, 3770-3774

144 B. Mangeat (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. Journal of Biological Chemistry 279, 14481-14483

145 B. Schröfelbauer , D. Chen and N.R. Landau (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceedings of the National Academy of Sciences of the United States of America 101, 3927-3932

146 H. Xu (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the United States of America 101, 5652-5657

147 L. Li (2008) APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication. Retrovirology 5, 72

148 S. Yamanaka (1995) Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proceedings of the National Academy of Sciences of the United States of America 92, 8483-8487

149 Z. Ao (2008) Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One 3, e1995

150 R.S. Aguiar (2008) Vpr.A3A chimera inhibits HIV replication. Journal of Biological Chemistry 283, 2518-2525

151 L.A. Green , Y. Liu and J.J. He (2009) Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. Journal of Biological Chemistry 284, 13363-13372

152 R. Goila-Gaur (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4, 61

153 M. Marin (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. Journal of Virology 82, 987-998

154 K.M. Rose (2005) Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Research and Human Retroviruses 21, 611-619

155 H.P. Bogerd (2008) Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. Journal of Virology 82, 11889-11901

156 H.P. Bogerd (2006) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Research 34, 89-95

157 H. Chen (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Current Biology 16, 480-485

158 B.D. Gooch and B.R. Cullen (2008) Functional domain organization of human APOBEC3G. Virology 379, 118-124

159 M. Kinomoto (2007) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Research 35, 2955-2964

160 H.P. Bogerd (2007) The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364, 486-493

161 B.P. Doehle , A. Schafer and B.R. Cullen (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288

162 Y. Hakata and N.R. Landau (2006) Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. Journal of Biological Chemistry 281, 36624-36631

163 M.A. Langlois (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Research 33, 1913-1923

164 Y. Dang (2008) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. Journal of Biological Chemistry 283, 11606-11614

165 Y. Dang (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. Journal of Virology 80, 10522-10533

166 Y. Han (2008) APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathogens 4, e1000095

167 M.M. Li , L.I. Wu and M. Emerman (2010) The range of human APOBEC3H sensitivity to lentiviral Vif proteins. Journal of Virology 84, 88-95

Y.L. Chiu and W.C. Greene (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annual Review of Immunology 26, 317-353

J.L. Smith (2009) Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends in Pharmacological Sciences 30, 638-646

R. Goila-Gaur and K. Strebel (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5, 51

S. Henriet (2009) Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC3G and APOBEC3F restriction factors. Microbiology and Molecular Biology Reviews 73, 211-232

M.H. Malim (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philosophical Transactions of the Royal Society of London Series B Biological Sciences 364, 675-687

168 M.D. Stenglein (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nature Structural & Molecular Biology Jan 10; [Epub ahead of print]

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 7
Total number of PDF views: 16 *
Loading metrics...

Abstract views

Total abstract views: 164 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 29th May 2017. This data will be updated every 24 hours.